转基因生物相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
181	Method for production of multiply-unsaturated fatty acids in transgenic organisms	JP2013270709	2013-12-27	JP2014128269A	2014-07-10	ZANK THORSTEN; BAUER JOERG; CIRPUS PETRA; ABBADI AMINE; HEINZ ERNST; QIU XIAO; VRINTEN PATRICIA; SPERLING PETRA; DOMERGUE FREDERIC; MEYER ASTRID; KIRSCH JELENA
PROBLEM TO BE SOLVED: To provide a method for producing multiply-unsaturated fatty acids in an organism into which nucleic acids have been introduced, the nucleic acids encoding polypeptides with Δ-5 elongase activity.SOLUTION: The method for the production of an oil and/or triacylglyceride which has increased content of long chain multiply-unsaturated fatty acids employs a vector with an isolated nucleic acid sequence encoding a polypeptide having Δ-6 desaturase, a Δ-5 desaturase, Δ-4 desaturase and/or Δ-6 elongase activity derived from Thalassiosira, Euglena, or Ostreococcus, and enzymes of an introduced transgenic organism: a microorganism, a nonhuman animal or a plant.
182	Method for production of multiple-unsaturated fatty acid in transgenic organism	JP2010232883	2010-10-15	JP2011087578A	2011-05-06	ZANK THORSTEN; BAUER JOERG; CIRPUS PETRA; ABBADI AMINE; HEINZ ERNST; QIU XIAO; VRINTEN PATRICIA; SPERLING PETRA; DOMERGUE FREDERIC; MEYER ASTRID; KIRSCH JELENA
<P>PROBLEM TO BE SOLVED: To provide a method for producing a multiple-unsaturated fatty acid in an organism, into which a nucleic acid coding for a polypeptide having Δ-5 elongase activity is introduced. <P>SOLUTION: There are provided a nucleic acid sequence coding for Δ-6 desaturase, Δ-5 desaturase, Δ-4 desaturase and/or Δ-6 elongase activity and derived from Thalassiosira, Euglena or Ostreococcus, and a genetic construction containing the nucleic acid sequence. <P>COPYRIGHT: (C)2011,JPO&INPIT
183	ＰｅｐＭｏＶ에 대한 내성이 증진된 고추의 형질전환체 및 그 제조방법	KR1020090108166	2009-11-10	KR1020110051539A	2011-05-18	한지학; 정민; 신선희; 최순호; 류기현
PURPOSE: A transformant plant with enhanced resistance to viral diseases due to PepMoV(pepper mottle virus) is provided to reduce virus damage and to reduce agricultural chemical use and labor. CONSTITUTION: A transgenic plant with enhanced PepMoV viral disease resistance is prepared by transforming a plant with a recombinant plant RNAi expression vector containing PepMoV-derived HC-Pro(helper component-proteinase) gene. The HC-Pro gene has a base sequence of sequence number 1. The recombinant RNAi expression vector is pK7GWIWG2(II)::HC-Pro vector. The plant is Capsicum annuum.
184	VERFAHREN ZUR HERSTELLUNG VON MEHRFACH UNGESÄTTIGTEN FETTSÄUREN IN TRANSGENEN ORGANISMEN	PCT/EP2008/052358	2008-02-27	WO2008104559A1	2008-09-04	ABBADI, Amine; FEUSSNER, Ivo; HOFFMANN, Mareike
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren, insbesondere langkettigen mehrfach ungesättigten Fettsäuren wie Arachidonsäure und/oder Eicosapentaensäure, in einem transgenen Organismus, indem Nukleinsäuren in den Organismus eingebracht werden, die für Polypeptide mit delta-6-Desaturase-, delta-6-Elongase- und/oder delta-5-Desaturase-Aktivität kodieren. Vorteilhaft stammen die delta-6-Desaturase und die delta-5-Desaturase aus Mantoniella squamata und die delta-6-Elongase aus Physcomitrella patens. Vorteilhaft wird in dem Organismus weiterhin ein Gen, das für eine omega-3-Desaturase kodiert, exprimiert. In einer weiteren vorteilhaften Ausführungsform des Verfahrens können weitere Nukleinsäuresequenzen, die für Polypeptide der Biosynthese des Fettsäure- und Lipidstoffwechsels kodieren, in dem Organismus exprimiert werden. Besonders vorteilhaft sind hierfür die Nukleinsäuresequenzen, die für eine delta-8-Desaturase-, delta-12-Desaturase-, delta-15-Desaturase, delta-4-Desaturase, delta-9-Elongase- und/oder delta-5-Elongase-Aktivität kodieren.
185	VERFAHREN ZUR HERSTELLUNG MEHRFACH UNGESÄTTIGTER FETTSÄUREN IN TRANSGENEN ORGANISMEN	PCT/EP2007/060554	2007-10-04	WO2008040787A2	2008-04-10	BAUER, Jörg; WETJEN, Tom
Die vorliegende Erfindung betrifft Polynucleotide aus Ostreococcus lucimarinus, die Desaturasen und Elongasen kodieren und zur rekombinanten Herstellung von mehrfach ungesättigten Fettsäuren eingesetzt werden können. Weiterhin betrifft die Erfindung Vektoren, Wirtszellen und transgene nicht-humane Organismen, die die Polynucleotide enthalten, sowie die von den Polynucleotiden kodierten Polypeptide. Schließlich betrifft die Erfindung noch Herstellungsverfahren für die mehrfach ungesättigten Fettsäuren und für Öl-, Lipid- und Fettsäurezusammensetzungen.
186	PROCESSES FOR PRODUCING POLYUNSATURATED FATTY ACIDS IN TRANSGENIC ORGANISMS	US15175278	2016-06-07	US20160304841A1	2016-10-20	Jörg Bauer; Tom Wetjen
The present invention relates to polynucleotides from Ostreococcus lucimarinus which code for desaturases and elongases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides, and to the polypeptides encoded by the polynucleotides. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions.
187	PROCESSES FOR PRODUCING POLYUNSATURATED FATTY ACIDS IN TRANSGENIC ORGANISMS	US12444193	2007-10-04	US20100088776A1	2010-04-08	Jörg Bauer; Tom Wetjen
The present invention relates to polynucleotides from Ostreococcus lucimarinus which code for desaturases and elongases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides, and to the polypeptides encoded by the polynucleotides. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions.
188	TRANSDERMAL TULOBUTEROL DELIVERY SYSTEM, METHOD AND COMPOSITION THEREFOR	PCT/US2004/037305	2004-11-05	WO2005046600A2	2005-05-26	LEBO, David, B.; LEE, Juny; LUISI, Vincent; RYOO, Je, Phil; TOIGO, Oliver, J., III
A transdermal tulobuterol delivery system, preferably in the form of a single-layer, drug-in-adhesive matrix patch, is disclosed comprising a relatively low, (less than five weight percent) concentration of tulobuterol base dissolved in a skin adhesive composition containing at least one skin permeation enhancer. The transdermal delivery system of this invention provides controlled release of the active ingredient, includes a relatively low concentration of tulobuterol within the skin-contacting adhesive formulation of a transdermal patch, and provides acceptable sustained transdermal delivery of the dissolved tulobuterol, as well as acceptable tack and. peel adhesive properties for the delivery device.
189	INDUCIBLE TRANSPOSITION IN TRANSGENIC ORGANISM USING TRANSPOSON VECTOR	PCT/GB0300065	2003-01-09	WO03056912A3	2003-10-16	CRAIG ROGER; SAVAKIS CHARALAMBOS; GROSVELD FRANK
A method of inducing transposition in a transgenic embryo is described, comprising the steps of (a) generating a first adult transgenic organism comprising within its genome one or more copies of a transposon; (b) generating a second adult transgenic organism comprising within its genome one or more copies of a gene encoding a transposase cognate for said transposon and/or a sequence capable of regulating expression of said gene encoding the transposase; (c) crossing the first adult transgenic organism with the second transgenic adult organism to provide a progeny which comprises, in the genome of one or more of its cells, both (i) one or more copies of the transposon and (ii) a gene encoding a transposase cognate for said transposon, wherein the gene encoding the transposase is under the control of one or more inducible regulatory sequences which permit expression of the transposase, and (d) inducing expression of said gene encoding the transposase in said embryo to cause mobilisation of said transposon within at least a portion of the tissues or cells of the progeny. Using the method, mobilisation of a transposon can advantageously be induced at predetermined stages of development of an embryo and the mutated gene of a single cell may be replicated in subsequent cell divisions, resulting in groups of cells which are essentially homogeneous for the transposed gene.
190	PRODUCTION OF TRANSGENIC AVIANS USING IMPROVED RETROVIRAL VECTORS	US15181987	2016-06-14	US20160353718A1	2016-12-08	Alex J. Harvey; Jeffrey C. Rapp
A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
191	PRODUCTION OF TRANSGENIC AVIANS USING IMPROVED RETROVIRAL VECTORS	US13179281	2011-07-08	US20120083033A1	2012-04-05	ALEX J. HARVEY; JEFFREY C. RAPP
A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
192	Transgenic organism expressing fungal MRP-like ABC transporters	US10492880	2002-10-16	US07358417B2	2008-04-15	Won Yong Song; Young Yeul Yang; YoungSook Lee; InWhan Hwang; Eun Woon Noh; Young Im Choi; Eun Hwa Jeong; Enrico Martinoia
The invention relates to a transgenic plant or yeast comprising a DNA molecule encoding fungal ATP-binding cassette (ABC) transporter protein, which confers resistance to, and/or accumulation of heavy metals and herbicides. The invention also relates to methods of producing transgenic plants expressing fungal YHL035C protein, which can be used for removing heavy metals and herbicides from polluted soil or water.
193	ENGINEERING PROTEIN POSTTRANSLATIONAL MODIFICATION IN TRANSGENIC ORGANISMS	PCT/US1996006121	1996-05-06	WO1996034966A2	1996-11-07	AMERICAN RED CROSS; LUBON, Henryk; DROHAN, William, N.; PALEYANDA, Rekha, K.
The invention relates to transgenic non-human multicellular organisms that contain polynucleotides for expressing proteins that alter posttranslational modification. In particular, the invention provides multiply-transgenic animals in which a first transgene encodes a first protein, a second transgene encodes a second protein, and expression of the second protein affects the posttranslational modification of the first protein in cells of said organism. Expression in preferred embodiments is in specific cells and the modified protein is secreted into a bodily fluid. The invention provides related methods, proteins and products. An example provides transgenic animals that express human Protein C and the processing protease PACE/furin in mammary glands and secrete both proteins into milk.
194	INDUCIBLE TRANSPOSITION IN TRANSGENIC ORGANISM USING TRANSPOSON VECTOR	EP03700348.0	2003-01-09	EP1465993A2	2004-10-13	Craig, Roger; Savakis, Charalambos; GROSVELD, Frank
A method of inducing transposition in a transgenic embryo is described, comprising the steps of (a) generating a first adult transgenic organism comprising within its genome one or more copies of a transposon; (b) generating a second adult transgenic organism comprising within its genome one or more copies of a gene encoding a transposase cognate for said transposon and/or a sequence capable of regulating expression of said gene encoding the transposase; (c) crossing the first adult transgenic organism with the second transgenic adult organism to provide a progeny which comprises, in the genome of one or more of its cells, both (i) one or more copies of the transposon and (ii) a gene encoding a transposase cognate for said transposon, wherein the gene encoding the transposase is under the control of one or more inducible regulatory sequences which permit expression of the transposase, and (d) inducing expression of said gene encoding the transposase in said embryo to cause mobilisation of said transposon within at least a portion of the tissues or cells of the progeny. Using the method, mobilisation of a transposon can advantageously be induced at predetermined stages of development of an embryo and the mutated gene of a single cell may be replicated in subsequent cell divisions, resulting in groups of cells which are essentially homogeneous for the transposed gene.
195	TRANSGENIC BIRD PRODUCING ERYTHROPOIETIN AND METHOD OF CONSTRUCTING THE SAME	US11910327	2006-02-24	US20090064351A1	2009-03-05	Shinji Iijima; Masamichi Kamihira; Kenichi Nishijima
The present invention has its object to provide a transgenic bird producing erythropoietin at high concentration levels as well as a method for constructing the same. The present invention provides a G0 transgenic chimera bird as obtained by incubating a fertilized avian egg, infecting the early embryo formed after egg laying, except for the blastoderm stage immediately following egg laying, with a replication-deficient retroviral vector containing a foreign erythropoietin gene and allowing the embryo to hatch.
196	PRODUCTION OF TRANSGENIC AVIAN ORGANISMS EMPLOYING EMBRYONIC STEM CELLS	US12376660	2007-08-09	US20100235937A1	2010-09-16	Isabelle Valarche; Luc Batard; Majid Mehtali
Method of culturing embryonic stem (ES) cells of avian origin includes the steps of: a) suspending ES cells originating from the blastoderm disk of fertilized un-incubated avian egg(s) in a basal culture medium supplemented with: insulin-like growth factor-1 (IGF-1) and ciliary neurotrophic factor (CNTF); and animal serum; and, optionally, at least one growth factor selected from among interleukin 6 (II-6), interleukin 6 receptor (II-6R), stem cell factor (SCF), fibroblast growth factor (FGF), leukemia inhibitory factor (LIF), interleukin 11 (II-11), oncostatin and/or cardiotrophin;b) seeding the suspension of ES cells obtained in step a) on a layer of feeder cells and further culturing the ES cells for at least 2 to 10 passages; c) optionally, removing at least one growth factor selected from among SCF, FGF, II-6, II-6R, LIF, oncostatin, cardiotrophin and II-11 from the culture medium; and d) further culturing the ES cells in the medium of step c) on a layer of feeder cells.
197	Method for producing arachidonic acid in transgenic organisms	US10769647	2004-01-30	US20050089879A1	2005-04-28	Ivo Feussner; Ellen Hornung; Christian Pernstich; Martina Korfei; Helmut Kindl
The invention relates to a method for the production of arachidonic acid in transgenic organisms, especially in transgenic plants and yeasts. The invention also relates to DNA sequences coding for a protein with enzymatic activity of a Δ5-desaturase from Phytophthera megasperma. The invention further relates to transgenic plants and plant cell and transgenic yeasts containing a nucleic acid molecule comprising a DNA sequence according to the present invention and having, on the basis thereof, an enhanced arachidonic acid synthesis in comparison with wild-type cells. The invention also relates to harvest products and propagating material of transgenic plants.
198	생식세포－특이적 유전자 발현조절 서열을 이용한 형질전환 조류 생산	KR1020100115328	2010-11-19	KR1020120054119A	2012-05-30	한재용; 서희원; 이형철; 박태섭; 정진경
PURPOSE: The production of transgenic aves using sequences for germ cell-specific gene expression is provided to analyze the differentiation or development of the priordial germ cells of aves into germ cells. CONSTITUTION: A method for producing transgenic aves includes the following: the priordial germ cells of aves are transformed based on a genetic vector containing a DAZL promoter as a germ cell-specific promoter, a NANOG promoter as a stem cell-specific promoter, and nucleotide sequence which encodes protein of revelation purpose; the transformed priordial germ cells of the aves are injected into accept media; and the transformed product of the aves is obtained. The protein is operatively bonded to the promoters.
199	トランスジェニック生物における多不飽和脂肪酸の製造方法	JP2016110891	2016-06-02	JP2016220683A	2016-12-28	ザンク,トルステン; バウア,ヨーグ; シルプス,ペトラ; アッバディ,アミネ; ハインツ,エルンスト; キウ,シャオ; ヴリンテン,パトリシア; スペルリング,ペトラ; ドメルグー,フレデリック; マイアー,アストリド; キルシェ,イェレーナ
【課題】Δ5−エロンガーゼ活性を有するポリペプチドをコードする核酸を導入した生物において多不飽和脂肪酸を製造する方法の提供。【解決手段】特定の配列を有する核酸配列、遺伝暗号の縮重の結果として、特定のアミノ酸配列をコードする核酸配列、または、特定の核酸配列に対してアミノ酸レベルで少なくとも40%の同一性を有し、かつΔ5−エロンガーゼ活性を有するポリペプチドをコードする核酸配列の誘導体よりなる群から選ばれる、Δ5-エロンガーゼ活性を有するポリペプチドをコードする単離された核酸配列。【選択図】なし
200	Transgenic organisms having tetracycline-regulated transcriptional regulatory systems	US09892227	2001-06-25	US20020152487A1	2002-10-17	Hermann Bujard; Manfred Gossen; Jochen G. Salfeld; Jeffrey W. Voss
Transgenic animals carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates in eucaryotic cells, and the second comprising a gene operably linked to a minimal promotor operably linked to at least one tet operator sequence, are disclosed. Isolated DNA molecules (e.g., targeting vectors) for integrating a polynucleotide sequence encoding a transactivator of the invention at a predetermined location within a second target DNA molecule by homologous recombination are also disclosed. Transgenic animals having the DNA molecules of the invention integrated at a predetermined location in a chromosome by homologous recombination are also encompassed by the invention. Methods to regulate the expression of a tet operator linked-gene of interest by administering tetracycline or a tetracycline analogue to an animal of the invention are also disclosed. The regulatory system of the invention allows for conditional inactivation or modulation of expression of a gene of interest in a host cell or animal.

5 6 7 8 9 10 11 12 13 14

IPRDB

热门服务

关于我们

友情链接

联系方式